Loading...
XSTO
VITR
Market cap1.21bUSD
Jul 09, Last price  
86.40SEK
1D
-2.26%
1Q
-10.65%
Jan 2017
11.63%
IPO
1,684.62%
Name

Vitrolife AB

Chart & Performance

D1W1MN
XSTO:VITR chart
P/E
P/S
3.40
EPS
Div Yield, %
1.27%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
22.53%
Revenues
3.44b
-4.68%
171,264,000188,939,000225,141,000274,626,000297,565,000356,115,000362,020,000452,738,000510,512,000722,370,000856,106,0001,046,217,0001,151,348,0001,480,132,0001,245,572,0001,680,804,0003,234,000,0003,512,000,0003,609,000,0003,440,000,000
Net income
-5.01b
L
15,199,00036,057,00029,995,00034,114,00029,182,00030,360,000333,772,00056,274,000109,109,000182,845,000190,368,000263,640,000309,697,000382,785,000286,845,000341,000,000394,000,000-3,851,000,000513,000,000-5,013,000,000
CFO
635m
-29.99%
23,784,00021,285,00042,793,00041,478,00048,399,00039,460,00059,930,000106,127,000145,666,000193,526,000181,262,000312,189,000349,435,000413,333,000356,448,000384,306,000636,000,000757,000,000907,000,000635,000,000
Dividend
Apr 30, 20251.1 SEK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
IPO date
Jun 26, 2001
Employees
1,102
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT